newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - CORBUS PHARMACEUTICALS HOLDINGS INC

Hello, everyone. Thank you for joining us. I'm Amin Makar. I am one of the biotech analysts here at Jefferies. I'm happy to introduce and welcome Yuval Cohen, CEO of Corbus. This is a fireside chat format. Thank you for having us here, Amin. So for those who may be new to this story, can you provide a one-minute intro? Sure. So Corbis is, we're a drug development company. We're based just south of Boston in Norwood, Massachusetts. There are about 40 of us. And we have an unusual pipeline. It's got two assets that are completely unrelated to each other. The one is a Nectin-4 ADC, and that's really the core of Corvus. CorvUS is an oncology company. But the other one is a highly peripherally restricted CB1 inverse agonist for obesity. Our Necten-4 acid is in a Phase III registrational study for oropharyngeal cancer. And our obesity acid just wrapped up a phase 1B 250-patient study. So it's been a busy week, and it's going to be a busy year. All right. Then let's just start and jump into the oncology acid. So you have this Tempo 1 phase 3 study, second line head and neck. and starting with this study can you walk us through the statistical assumptions you have there the rationale for having this dual primary endpoint while for example PETO if I'm not mistaken has only OS as a primary endpoint and your expectations for the treatment arm and control lot. Got it. Lots of very good questions, some of which we don't really want to answer for competitive reasons, as you would expect. I would start philosophically by saying that, actually start with GenMap. So GenMAP had their data out, and I think one of the important things about GenMaps is they laid out not only a very sensible way of going about this, but actually a very enviable way of going about this so the rule of thumb would be pretty much emulate the gen map strategy so in second line we have the strategy we have is actually their original strategy which was an accelerated approval strategy which they maintained in their front line so accelerated approval based on ORR. The study then continues, and finally is based, the final approval is based on OS. Very, very sensible. The statistical assumptions are very sensible to what all of us assume that GenMab have done. One thing I mean in audience to think about is GenMap, I think, very masterfully in the front line, and for that matter, we're pretty sure in the second line, We're very, very thoughtful in terms of patient stratification, et cetera. That's something that we would absolutely want to emulate. It's a very, very sensible and clever way of going about things. The important thing for us in the second line, I mean, is a couple of things. One, study started. The assumption for the control arm you just asked is based on a variety of studies out there. It will be very interesting at some stage to see what GenMAP obviously report. But the assumption of the second of the control ARM is an ORR round about the 20%. That sounds about right. And so your delta above that should be sufficient to cross that finishing line. certainly what we are hearing, and I think you've mentioned that as well in your reports, is the threshold for the KOLs out there for a second line in oral pharyngeal, for that matter in head and neck, is anything north of 30% is clinically desirable and actionable. The figure for the front line is 50%, so it's obviously a higher bar in the front line. And so the way we've done And our statistical assumptions is we know what we've gotten in our data to date, in our phase one, phase two. We know what the control arm should be doing, and so you power the study appropriately. Okay, sounds good. You mentioned about the patient certification and general strategy. Anything more into that? Is that related to the HPV status? Absolutely. It's really the only thing out there. It's the same logic. Their logic applied to head and neck in general. And if anything, that's a much more diverse population. We have an easier job than they do. We focus only on oral pharyngeal. And a reminder, something like 85% of oral pharyngial patients are HPV positive to begin with. But again, the way GenMAP approached it was so thoughtful and so well executed in retrospect that we would absolutely want to emulate their strategies. And have you had any discussions with the FDA if there is a bar for the ORR, or it's just a stat-sig should be good enough for it? Yeah, so we have alignment with the FTA. Again, just like GenMab, we are not going to disclose the specific details, but it's sensible. There's not a lot of mystery, I mean, around, as I said, what looks like good, what is a healthy delta between us and a control, We shouldn't expect any surprises. This one is not complicated. So it looks like the BLA is expected around second half of 28. What change and how much OS follow-up do you expect to have by that time point? And obviously this means probably data by first half of 20. I think that's the key. The key is getting that ORR data, sufficient follow-up, then submission, and yes, it has to be robust enough and directionally promising enough to be able for us to go ahead and pull the trigger on a submission. And so you're enrolling oropharyngeal patients regardless of HPV status, is that correct? Correct. So the primary selection is oropharyngial. It's anatomical. that's really important. We do not want to have a primary selection based on HPV status, and the same reason that GenMAP did not want it. Having said that, again, then you do a follow stratification, which GenMap did, which was immensely sensible. And there's a logic to that. I mean, you want to make sure that your final population reflects what is seen out there in, as it were in the wild or in the real-world data and is not artificially skewed, for example, by things like geography, et cetera. Okay. And the HPV certification would be a retrospective or prospective work? Well, the advantage of P16 is so many patients these days, especially in the territories that we're focusing on, by the time they get to second line, we know what their P16 value is. So it's relatively straightforward. Okay. And how much could these HPV-negative patients could dilute your treatment effect? Because we saw some good responses in HPV positive, but then not so much in HPP negative. That's right. It's not, having said that, it's interesting. One of our best responders was an HPV negative patient, right? And so I think the key here is, again, the same logic that GenMap applied, looking at a similar situation, one population does a lot better, but the other population still has tremendous value in it, especially in terms of a label, and that's our approach as well. So, assuming P2O moving to frontline setting... That's a very safe assumption. Yeah. How would that affect the tempo, one patient baselines, the control arm, and then the enrollment pace, I'm assuming? Would that affectthe baseline of patients having an EGFR treatment in the front line while joining your study? So we anticipate the effect to be minimal, if any. just looking at the calendar, by the time they are out there on the market, our enrollment will either have been done or overwhelmingly completed. It also opens, the PITO data and frontline opens an interesting opportunity for us. Paradoxically, I mean, it actually removes PITOs as an issue for us in the second line setting. PETO now is going to be a front-line drug. By the time they finally read out their second line, remember their second-line started as an accelerated approval program and was then, I guess I can use the term, downgraded into a normal, as it were, approval. They're just not going to become a front line drug. It's not going be an issue for us in terms of patients in second- line competing for PETO. That's a big advantage. And then ultimately, the challenge and opportunity that PETO presents to us is not our second-line setting. It's our potential in front-line and oral pharyngeal. I see. And just as a long-term strategy, assuming the patients are going to be post-EGFR at some point, the second- line patients, how should we think about these type of patients getting a Nectin-4 treatment? Have you had any data on that side? We did have a few patients in our Phase II that were post-EGFR, including post-PETO. There were responders amongst them. Biologically, it shouldn't particularly interfere, especially since, again, The HPV-positive patients tend to not be the patients that typically would respond well to EGFR anyway. Nectin-4 should not be affected by EGF-R therapy. But I think the key, and I wonder, I mean, if that's sort of the follow-up question in a sense, is, right, so second line, at some stage patients will fail front line. They'll get to second line. PETO is not going to be an issue for us in second line." But let me take everybody back to what about the front line, right? And so in the front lines, the interesting opportunity and challenge is, is there going to be a room in the frontline for PETO with a head and neck agnostic label, assuming they get it, coexisting with CRB701, which now has an official name, very difficult to pronounce, I should point out, but sutantitag invidotin, sutai, is there room for a SUTA-E in oral pharyngeal patients to coexist? And I think the answer is yes, if the delta in efficacy in that population is big enough. And so for that, we need two pieces of data that we don't know. We need to see how did PETO do in those oral pharyngial patients. In their case, it will be defined as HPV positive. And then we need to see how do we do in the oral pharyngeal patients. If that delta is sufficiently large enough, then that is our opportunity, and that's how we coexist. All right. So with a reminder, I mean, sir, if I may, that what we don't need to worry about is either by Kara or Johnson & Johnson because by definition they will exclude the patients that we're interested in. Makes sense. maybe talking a little bit about safety. Ocular events led to a number of dose reductions and disruptions among the oropharyngeal responders. How much of the planned dose were patients actually able to receive as a median or mean? So we have that. It occurred to me that we don't have it in our deck. We have it on our ASCO poster, which is on our website. So where we broke down for head and neck the safety, especially the ocular safety, for both doses, so the 3.6 as a standalone. And, I mean, if I remember correctly, something like one-third of them had an interruption. So two-thirds had no interruption, one- third had an interruption. The interruption I think we commented on it previously on average was about a week additional. And so it's not particularly impactful. And certainly for those who are not interrupting, it's not impactful at all. And how does this ocular tox work? Is that something that chronically stays with the patient or it shows up at the beginning and it goes away once this interruption happens? It's wonderfully similar to what we're seeing with so many ADCs now. So reminder, it is the surface of the eye. It's keratitis and dry eye. Like so many other ADCs now, I mean, the pattern is very similar. If it's going to happen, it tends to happen at the beginning. It tends to be a wave. It is almost always resolvable. Everybody, all of us ADC companies use the same strategy, which is if you have ocular issues already, you're not going to be on the drug. If you are on the drug and you start to see ocular issues, intervene early, and it's eye drops plus interruptions that are temporary, dose dial downs that are typically temporary as well. And so it's a wave that goes up and down and then either goes away or just simmers. The reason that's so interesting, I mean, is it's very, very, very different to peripheral neuropathy, which of course is the issue with PADCET, for example. Peripheral neuropathy tends to be a time-to-event. So it's like a Russian roulette. The longer the time is, the higher your chances of getting it. PeripherAL neuropathies are debilitating. And the biggest challenge with peripheral neuropathy, it is often, sadly, irreversible. So when a patient starts to get peripheral neuthropathy, for the clinician, that sadly is a sign of, okay, this patient is approaching the end of their tolerability. Ocular isn't anything like that. they know they're going to crest through it. The key is just educating the oncologists. So, for example, the gynecologists are very familiar with it because of TIVDAC. The urologists are familiar because of PADSEV. And in head and neck, they're becoming more and more familiar becauseof us. All right. And for the TEMPO-1 study, what's the strategy for using PROFI? Any changes versus what you had in the Phase II study? Standard. It's, I mean, it has become now, there was an interesting review recently, and I'm trying to remember how many ADCs have this now, and it's probably about a dozen, and there's more any day. It is part and parcel of having, especially MMAE, these hyper-stable new ADCs. That is the price you pay for it. All right. A quick question on your partner in China, CSBC. They are starting a phase three in cervical cancer, if I'm not mistaken. And they chose a 2.4 milligram per kick every two weeks versus your 3.6 every three weeks. Just wanted to understand why these two programs landed in a different regimen. It's very interesting, and to add to that, their bladder program still uses the 3.6 Q3 weekly. So a couple of thoughts. The data, and they recently presented the data, between the 3,6 Q2 weekly and the 2,4 Q2 weekly is almost indistinguishable. It is a peculiarity of the Chinese FDA that requested they do that, but only in one of their indications. It's one of those points where China is a little bit different than what we are. and that's fine it's a peculiarity of China the bottom line is we were very reassured to see how similar their data is both within China the 3.6 and the 2.4 Q3 and also compared to us let's move on to your front line study for the front line in combination with Pembro So what's the right bar there to think about? We have the GEM map in front line, but we don't know the details exactly. And also, how many patients should we expect to see in the readout next year? So the bar for effect for desirable or applicable, clinically applicable clinical effect in the front line is an OR north of 50%. That really is very, very consistent with KOL, and I know you've spoken to a bunch of KOLs about this. they're unanimous it's north of 50 we'll see where PETO is on the HPV positive it seems a little bit hard to believe they got that high in HPV positive and some of their answers indicate that while they saw clinical benefit rightly so it is worthwhile noting that they did not disclose what their clinical benefit is and that's perfectly fine that's fair if we look at the data sets that we have for our peers so peter were four responses out of eight in the early studies we have the other egfr bispecifics so we've got by kira and j and j at around 25 and 27 which really just feels like pember on its own and then we have this really remarkable early data set, tiny data set from PADSEV with 9 out of 11 that will be incredible we've got to be better than 50 and the closer we are to that PADSAV the stronger the delta becomes between us and PETO and again that really is going to be the key alright so So, going back to the competitive landscape, Pixis' micro is already in play in the second line. They already have some survival data across HPV groups, which looks comparable across both HPV positive and negative. How should we think about the differences between your second-line data versus them? And how important will the OS be in separating the two programs? When should we see the OS data from your program as well? So the first thing it goes without saying is the more options patients have, the better. At the moment, that second line, especially oral pharyngeal, is a desert. It's horrific. They're not going to get cetuximab. And so they're getting another round of chemo. Half of the patients eligible for second line in the U.S. elect to not even get anything. That's how horrible that is. It's a real human tragedy and obviously a medical opportunity, a clinical commercial opportunity. I think that the drugs are very, very different. Our durability has obviously matured since ASCO. So we look forward to updating that sometime next year. So we focus on oral pharyngeal. Our target, Nectin-4, is expressed primarily in that tumor type. PXIS is a very different mechanism of action. It uses tumor microenvironment. It's a bystander effect. I think it will be very, very interesting to see how we differ in the oral pharyngial data set. And then equally importantly will be tolerability. What is helpful is we are meaningfully ahead of them, right? Our second line is in a registrational study. It has started. We will be wrapping up relatively shortly, given that it's an accelerated pathway. They are not there yet. But competition is a good thing, and these are very, as I said, very, very different options. um their interesting thing about them is they go for the hpv negative they have an effect on hpv negative that's somewhere where we don't compete the flip side of it of course is i'm a phantom i've just got approval for that population as well and so each one of us is looking at very different type of of settings in the second line i think all right uh moving to the obesity program I just wanted to discuss, you presented at Obesity Week, the feedback you received there, the next steps you have in progress, and the expected timings. Feedback was immensely informative and really uniform, which is so encouraging. On efficacy, a lot of excitement about the efficacy. KOLs agree with us. This looks very similar to an oral GLP-1 using a completely orthogonal mechanism. They want orthogonal mechanisms for GLP1. Very reassuring in terms of the psychiatric adverse events. No pushback from KOLs. This does not cause them concern. They agreed with us that it is in line with what's been seen with GLP2s. A lot of enthusiasm around our mild GI adverse event. a lot of interest in seeing combinability, particularly with orfaglipron, something that we would also be very interested in doing. And of course, a lot OF interest in saying what longer study looks like. For the KOLs, it's not so much for the safety. I think they have a very high degree of comfort with the safety, very curious to see where we end up at 52 weeks. Their assumption, which we think that we agree with, is at one year, if this looks anything like monolunar band, we're looking at north of 10%, probably something that lies between orthoglipron and oral Wegovy, with a completely orthogonal mechanism of action. All right. And maybe if we can talk about the psychiatric events you saw in Canyon 1. Can you break out the events by dose, severity, and discontinuation? In particular, when did usually these irritability issues emerge, and did it resolve after patients stopped the treatment immediately, or how did that work? So irritability is the only thing we have that's there. They're not dose-dependent. They happen right at the beginning, so mostly on 20, when the patients first meet the drug. They all resolve. They're all mild and none lead to discontinuations. All right. Easy. Sounds good. This has been a great conversation. Thank you very much for joining us. Thank you so much. Always wonderful talking to you. Thank you, everyone. Thank you. Thank you everyone.

Company
CORBUS PHARMACEUTICALS HOLDINGS INC
Keywords
CORBUS PHARMACEUTICALS HOLDINGS INC